Kevin Finney is the founder of Autobahn Therapeutics. Autobahn Therapeutics has raised $76M in total funding. Latest round: Series B.
Kevin Finney is the Chairman and CEO of Autobahn Therapeutics, a San Diego-based biotechnology company focused on developing regenerative medicines for CNS disorders. He led the company's launch with a $76 million Series B financing round in June 2020.
Full founder directory · Investor directory · Company funding database · Fundraising library